Anuh Pharma Ltd
Anuh Pharma Q3 FY24: Capex ₹20 Cr
Q3 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹172Cr
- Net profit
- ₹19Cr
- Margin
- 14%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Anuh Pharma Ltd Q3 FY24 key numbers
- Revenue
- FY23 Operating Revenue: Rs. 527.49 Cr vs Rs. 486.65 Cr FY22, up 8% YoY.
As stated in Anuh Pharma Ltd's Q3 FY24 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Anuh Pharma Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY24 Revenue: Rs. 172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Quarterly EBITDA (Q3 FY24): Rs. 27.65 Cr (38% YoY increase from Rs. 20.11 Cr in Q3 FY23).
From Anuh Pharma Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY24 Revenue: Rs. 172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23.
- 9 months ended 31/12/2023 Revenue: Rs. 483.11 Cr vs Rs. 370.18 Cr for 9M FY22, up 31% YoY.
- FY23 Operating Revenue: Rs. 527.49 Cr vs Rs. 486.65 Cr FY22, up 8% YoY.
- Q3 FY24 EBITDA: Rs. 27.65 Cr, up 38% QoQ.
- Company plans Rs. 20 Cr capex in FY25 to enhance capacity by 70 KL.
- Outlook highlights:
- Increase contribution from new geographies (Japan, Vietnam, South Korea).
- Focus on expanding market share in corticosteroids with increased manufacturing capacity to 12 MTPA.
- Tap opportunities with CEP-approved products (Gliclazide, Azithromycin) in Europe.
2 more points from Anuh Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex planned: Rs 20 crore investment in existing site for FY25 (Page 6).
- Capacity expansion: Addition of 70 KL of volume capacity from this Rs 20 crore investment (Page 6).
- Manufacturing capacity enhancement at L&L site for Corticosteroids increased to 12 MTPA (Page 30).
2 more points from Anuh Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Anuh Pharma Ltd — Quarterly revenue & net profit
Anuh Pharma Ltd Q3 FY24 results — key figures
| ₹ Cr | Q3 FY24 | Q2 FY24 | QoQ |
|---|---|---|---|
| Revenue | 172 | 150 | +14.7% |
| Operating profit (EBITDA) | 24 | 18 | +33.3% |
| Operating margin | 14% | 12% | +2 pp |
| Profit before tax | 25 | 18 | +38.9% |
| Net profit (PAT) | 19 | 14 | +35.7% |
| EPS (₹) | 1.91 | 1.38 | +38.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt (Q3 FY24)
Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key concall takeaways from Wockhardt Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q3 FY24)
Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3…
- Bharat Parenterals (Q3 FY24)
Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key concall takeaways from Bharat Parenterals Ltd's Q3 FY24 earnings call — and how it ranks against…
- Themis Medicare (Q3 FY24)
82.51 Cr, down 7.06% year-on-year from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q3 FY24 results?
Q3 FY24 Revenue: Rs. 172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Quarterly EBITDA (Q3 FY24): Rs. 27.65 Cr (38% YoY increase from Rs. 20.11 Cr in Q3 FY23).
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Capex planned: Rs 20 crore investment in existing site for FY25 (Page 6). - Capacity expansion: Addition of 70 KL of volume capacity from this Rs 20 crore investment (Page 6). - Manufacturing capacity enhancement at L&L site for Corticosteroids increased to 12 MTPA (Page 30). - R&D facility: Dedicated 10,000 sq.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.